2.78
price down icon4.47%   -0.13
after-market Dopo l'orario di chiusura: 2.93 0.15 +5.40%
loading
Precedente Chiudi:
$2.91
Aprire:
$2.9
Volume 24 ore:
81,432
Relative Volume:
0.59
Capitalizzazione di mercato:
$70.25M
Reddito:
-
Utile/perdita netta:
$-13.27M
Rapporto P/E:
-16.95
EPS:
-0.164
Flusso di cassa netto:
$-7.70M
1 W Prestazione:
+14.64%
1M Prestazione:
+48.66%
6M Prestazione:
+150.45%
1 anno Prestazione:
+135.59%
Intervallo 1D:
Value
$2.69
$2.90
Intervallo di 1 settimana:
Value
$2.41
$2.92
Portata 52W:
Value
$0.8075
$3.11

Okyo Pharma Limited Stock (OKYO) Company Profile

Name
Nome
Okyo Pharma Limited
Name
Telefono
-
Name
Indirizzo
-
Name
Dipendente
3
Name
Cinguettio
Name
Prossima data di guadagno
2024-09-30
Name
Ultimi documenti SEC
Name
OKYO's Discussions on Twitter

Confronta OKYO con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
OKYO
Okyo Pharma Limited
2.78 70.25M 0 -13.27M -7.70M -0.164
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
459.62 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
547.36 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
331.91 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
543.48 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
245.49 28.51B 3.81B -644.79M -669.77M -6.24

Okyo Pharma Limited Borsa (OKYO) Ultime notizie

pulisher
Jun 18, 2025

OKYO Pharma (NASDAQ:OKYO) Shares Down 13.7% – Should You Sell? - Defense World

Jun 18, 2025
pulisher
Jun 16, 2025

OKYO Pharma Limited's (NASDAQ:OKYO) market cap rose US$31m last week; individual investors who hold 58% profited and so did insiders - simplywall.st

Jun 16, 2025
pulisher
Jun 14, 2025

OKYO Pharma Limited's (NASDAQ:OKYO) market cap up US$38m last week, benefiting both individual investors who own 58% as well as insiders - Yahoo Finance

Jun 14, 2025
pulisher
Jun 12, 2025

OKYO Pharma To Showcase Urcosimod Development At BIO International Convention Next Week - RTTNews

Jun 12, 2025
pulisher
Jun 11, 2025

OKYO Pharma poised for breakout as Phase 2 trial nears results: analysts - Proactive Investors

Jun 11, 2025
pulisher
Jun 11, 2025

Small cap wrap: Alvopetro, EnWave, OKYO Pharma... - Proactive financial news

Jun 11, 2025
pulisher
Jun 11, 2025

Market movers: Chewy, Victoria's Secret, Lockheed Martin, OKYO Pharma... - Proactive financial news

Jun 11, 2025
pulisher
Jun 11, 2025

Goldman Small Cap Research Issues New Research Update on OKYO Pharma Limited - ACCESS Newswire

Jun 11, 2025
pulisher
Jun 11, 2025

Goldman Research Boosts OKYO Pharma Target 60% as Eye Drug Trial Ends Early: Key Catalyst Ahead - Stock Titan

Jun 11, 2025
pulisher
Jun 11, 2025

OKYO Pharma CEO to Present Urcosimod Development at Bio International Convention - TipRanks

Jun 11, 2025
pulisher
Jun 11, 2025

OKYO Pharma to Present at the Bio International Convention - GlobeNewswire

Jun 11, 2025
pulisher
Jun 11, 2025

OKYO Pharma CEO to Present Urcosimod Development for Neuropathic Corneal Pain at Bio International Convention 2025 - Nasdaq

Jun 11, 2025
pulisher
Jun 11, 2025

First Treatment for Neuropathic Corneal Pain? OKYO Pharma Reveals Clinical Progress at BIO 2025 - Stock Titan

Jun 11, 2025
pulisher
Jun 11, 2025

OKYO Pharma announces presentation at BIO International Convention - Proactive financial news

Jun 11, 2025
pulisher
May 27, 2025

OKYO Pharma (NASDAQ:OKYO) Stock Price Up 0.5% – Should You Buy? - Defense World

May 27, 2025
pulisher
May 20, 2025

OKYO Pharma stock soars to 52-week high of $1.75 - Investing.com Australia

May 20, 2025
pulisher
May 20, 2025

OKYO Pharma stock soars to 52-week high of $1.75 By Investing.com - Investing.com India

May 20, 2025
pulisher
May 19, 2025

OKYO Pharma has dry eyes as a lucrative prize in its sights - Proactive Investors

May 19, 2025
pulisher
May 19, 2025

OKYO Pharma CEO to Present at Boston Drug Discovery Summit - TipRanks

May 19, 2025
pulisher
May 19, 2025

OKYO Pharma Limited CEO to Present on Urcosimod Development for Neuropathic Corneal Pain at GPCRs-Targeted Drug Discovery Summit - Nasdaq

May 19, 2025
pulisher
May 19, 2025

OKYO Pharma to Present at the GPCRs-Targeted Drug Discovery Summit - GlobeNewswire

May 19, 2025
pulisher
May 19, 2025

OKYO Pharma Advances First-Ever Treatment for Neuropathic Corneal Pain at Major Drug Summit - Stock Titan

May 19, 2025
pulisher
May 19, 2025

OKYO Pharma CEO to present drug research for debilitating eye pain at Boston summit - Proactive financial news

May 19, 2025
pulisher
May 06, 2025

OKYO Pharma ("OKYO" or the "Company")announces issuance of U.S. Patent No. 11,254,720 covering OKYO’s dry eye drug candidate OK-101 for use to treat ocular neuropathic pain - Barchart.com

May 06, 2025
pulisher
May 06, 2025

OKYO Pharma’s (OKYO) Buy Rating Reaffirmed at HC Wainwright - Defense World

May 06, 2025
pulisher
May 05, 2025

Neuropathic Ocular Pain Market Expected to Experience Major - openPR.com

May 05, 2025
pulisher
May 05, 2025

Neuropathic Ocular Pain Market Expected to Experience Major Growth by 2034, According to DelveInsight | Novartis, OKYO Pharma, AbbVie Inc., Aciex Therapeutics, Novaliq, Oculeve and Allergan, Adverum - Barchart.com

May 05, 2025
pulisher
May 05, 2025

Allergic Conjunctivitis Pipeline 2025: FDA Approvals, Therapies, Clinical Trials, and Latest Developments Unveiled by DelveInsight | Bausch & Lomb Inc, Aldeyra Therapeutics, Vanda Pharma, OKYO Pharma - Barchart.com

May 05, 2025
pulisher
May 05, 2025

OKYO Pharma Limited (NASDAQ:OKYO) Sees Significant Decrease in Short Interest - Defense World

May 05, 2025
pulisher
May 03, 2025

ADS Program collapse - Investegate

May 03, 2025
pulisher
May 02, 2025

FDA Grants OKYO Pharma Fast Track Designation to Urcosimod for Neuropathic Corneal Pain - marketscreener.com

May 02, 2025
pulisher
May 02, 2025

OKYO moves toward FDA talks after eye drug trial – ICYMI - Proactive financial news

May 02, 2025
pulisher
May 01, 2025

FDA grants fast track to OKYO Pharma’s neuropathic pain drug - Investing.com Australia

May 01, 2025
pulisher
May 01, 2025

Small cap wrap: GoviEx, NextSource Materials, Voyageur Pharmaceuticals, OKYO Pharma... - Proactive financial news

May 01, 2025
pulisher
May 01, 2025

FDA grants fast track to OKYO Pharma’s neuropathic pain drug By Investing.com - Investing.com Nigeria

May 01, 2025
pulisher
May 01, 2025

FDA grants fast track designation to OKYO Pharma’s urcosimod for treatment of neuropathic corneal pain - Ophthalmology Times

May 01, 2025
pulisher
May 01, 2025

OKYO Pharma’s Urcosimod Receives FDA Fast Track Designation for Neuropathic Corneal Pain - TipRanks

May 01, 2025
pulisher
May 01, 2025

FDA Fast-Tracks Novel Eye Pain Drug: OKYO's Urcosimod Targets Untreated Corneal Condition - Stock Titan

May 01, 2025
pulisher
May 01, 2025

OKYO Pharma secures FDA fast-track designation for urcosimod for neuropathic corneal pain - Proactive financial news

May 01, 2025
pulisher
Apr 30, 2025

OKYO Pharma accelerates neuropathic corneal pain treatment with early closure of Phase 2 trial - Proactive financial news

Apr 30, 2025
pulisher
Apr 30, 2025

Market movers: Snap, Super Micro Computer, OKYO Pharma... - Proactive financial news

Apr 30, 2025
pulisher
Apr 30, 2025

Okyo Pharma announces plans to accelerate development of urcosimod - TipRanks

Apr 30, 2025
pulisher
Apr 30, 2025

OKYO Pharma Accelerates Urcosimod Development for Neuropathic Corneal Pain - TipRanks

Apr 30, 2025
pulisher
Apr 30, 2025

OKYO Pharma speeds up NCP drug development - Investing.com

Apr 30, 2025
pulisher
Apr 30, 2025

OKYO Pharma Announces Plans to Accelerate the Clinical - GlobeNewswire

Apr 30, 2025
pulisher
Apr 30, 2025

OKYO Pharma Limited Announces Plans to Accelerate the Clinical Development of Urcosimod to Treat Neuropathic Corneal Pain - marketscreener.com

Apr 30, 2025
pulisher
Apr 30, 2025

OKYO Pharma accelerates clinical development of urcosimod for neuropathic corneal pain - Proactive financial news

Apr 30, 2025
pulisher
Apr 27, 2025

Press Release Distribution & PR Platform - ACCESS Newswire

Apr 27, 2025
pulisher
Apr 23, 2025

OKYO Pharma Announces First Patient Dosed in the First Clinical Trial to Treat Neuropathic Corneal Pain - ADVFN

Apr 23, 2025
pulisher
Apr 22, 2025

OKYO Pharma Announces Start of Phase 2 Clinical Trial to Treat Patients with Neuropathic Corneal Pain - ADVFN

Apr 22, 2025
pulisher
Apr 08, 2025

Kyverna Therapeutics (NASDAQ:KYTX) and OKYO Pharma (NASDAQ:OKYO) Financial Review - Defense World

Apr 08, 2025

Okyo Pharma Limited Azioni (OKYO) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$20.30
price down icon 0.68%
$36.37
price up icon 0.50%
$24.55
price up icon 8.53%
$97.80
price down icon 0.45%
$110.00
price up icon 1.61%
biotechnology ONC
$245.49
price up icon 0.48%
Capitalizzazione:     |  Volume (24 ore):